Brazil Pharmaceutical Contract Manufacturing Market Size, Share and Growth Forecast 2035

The Brazil pharmaceutical contract manufacturing sector is gaining strategic importance as pharmaceutical companies seek scalable production, regulatory-compliant manufacturing, cost efficiency and access to established local manufacturing infrastructure. Brazil’s large pharmaceutical industry, domestic demand and growing production capabilities create opportunities for contract manufacturing organizations serving prescription medicines, generics, hospital products, oncology, biologics and other pharmaceutical segments.

Local manufacturers are also expanding capacity. EMS’s Novamed announced a R$300 million investment to expand its Manaus manufacturing facility and establish a research, development and innovation center, with planned production capacity of up to 2.5 billion tablets per month.

Eurofarma is another important participant. Its CMO business has more than 50 years of experience and provides manufacturing, packaging and other outsourcing services. The company reported 8%–10% real growth in its CMO business in 2025.

Contract Pharmaceutical Manufacturing Market Trends for 2026

Download Sample : https://www.towardshealthcare.com/download-sample/6790

The global contract pharmaceutical manufacturing market size was estimated at USD 232.32 billion in 2025 and is predicted to increase from USD 255.41 billion in 2026 to approximately USD 599.3 billion by 2035, expanding at a CAGR of 9.94% from 2026 to 2035.

Brazil Pharmaceutical Contract Manufacturing Market Size and Growth

The Brazil pharmaceutical contract manufacturing opportunity is being influenced by increasing outsourcing, pharmaceutical portfolio expansion, manufacturing capacity investments, demand for generic and branded medicines, and the need for local regulatory and production capabilities.

For a strong TH page, this section should include:

• Historical market size
• 2025 base-year value
• 2026 estimate
• 2035 forecast
• CAGR
• Revenue contribution by manufacturing type
• Domestic vs international clients
• Pharmaceutical dosage-form analysis

Why Is Pharmaceutical Contract Manufacturing Growing in Brazil?

Growing pharmaceutical manufacturing base

Brazil has an established pharmaceutical manufacturing ecosystem supported by domestic manufacturers, multinational companies, contract manufacturers and suppliers.

Increasing outsourcing

Pharmaceutical companies can use CMOs to reduce the need for additional internal manufacturing capacity while accessing established facilities, quality systems and regulatory capabilities.

Eurofarma explicitly offers full-service outsourcing covering material procurement, manufacturing and primary and secondary packaging, as well as selective manufacturing services and dedicated projects.

Expansion of local manufacturing capacity

Investment in manufacturing infrastructure is another important growth indicator. EMS’s Novamed expansion in Manaus is designed to significantly increase tablet production while adding PD&I infrastructure.

Demand for cost-efficient medicines

Brazil’s large generics and pharmaceutical sectors create opportunities for manufacturers that can provide high-volume, compliant and cost-efficient production.

Brazil Pharmaceutical Contract Manufacturing Market Trends

Shift toward specialized manufacturing

Contract manufacturers are increasingly competing on capabilities rather than basic production capacity.

Important areas include:

• Oncology manufacturing
• Hormonal products
• Sterile injectables
• Biologics
• Biosimilars
• High-potency drugs
• Complex formulations
• Hospital products

Cristália, for example, operates across pharmaceutical, pharmaceutical-ingredient and biotechnology activities and reports capabilities spanning biotechnology and oncology-related manufacturing.

Biologics and biotechnology opportunity

Biotechnology manufacturing could become an important long-term opportunity as pharmaceutical pipelines increasingly include complex biological products.

For CMOs, this creates demand for specialized facilities, quality systems, analytical capabilities and regulatory expertise.

Local manufacturing and supply-chain resilience

Brazilian manufacturers are also strategically important because the country remains dependent on imported pharmaceutical ingredients. Cristália states that Brazil imports approximately 90% of the APIs used in medicine production, while the company produces around 60% of the APIs it requires for its own medicines.

This creates opportunities around domestic manufacturing, API localization and supply-chain diversification.

Brazil Pharmaceutical Contract Manufacturing Market Segmentation

By Service

• Pharmaceutical manufacturing
• API manufacturing
• Drug product manufacturing
• Packaging
• Analytical services
• Formulation development
• Technology transfer

By Drug Type

• Generics
• Branded medicines
• Over-the-counter medicines
• Specialty pharmaceuticals
• Oncology drugs
• Hormonal drugs
• Biologics
• Biosimilars

By Dosage Form

• Tablets
• Capsules
• Injectables
• Liquids
• Creams and ointments
• Other dosage forms

By Client Type

• Large pharmaceutical companies
• Biotech companies
• Specialty pharmaceutical companies
• Generic drug manufacturers
• International pharmaceutical companies

Brazil Pharmaceutical Contract Manufacturing Market Companies

The competitive landscape includes established pharmaceutical manufacturers with third-party production capabilities as well as specialized CMOs.

Eurofarma

Eurofarma is one of the most relevant companies to track because it explicitly operates a CMO and third-party manufacturing business. It has 10 manufacturing plants across Latin America and operates in 20 countries.

Its CMO services include complete manufacturing, packaging, selective production stages and dedicated manufacturing projects.

EMS / Novamed

EMS is strengthening domestic manufacturing through Novamed’s Manaus expansion. The R$300 million investment includes additional manufacturing capacity and a PD&I center.

Cristália

Cristália operates pharmaceutical, pharmaceutical-ingredient and biotechnology businesses and has manufacturing and R&D capabilities spanning multiple pharmaceutical categories. The company reports 131 patents and approximately 30 new-drug projects under development.

Other companies to evaluate in the competitive landscape should be included only after confirming their direct participation in Brazil’s contract manufacturing segment.

Brazil Pharmaceutical Contract Manufacturing Market Opportunities

The strongest opportunities through 2035 are likely to be concentrated around:

Specialized manufacturing: Increasing complexity of pharmaceutical products can create demand for technically differentiated CMOs.

Biologics and biosimilars: Expanding biological-drug pipelines can increase demand for specialized manufacturing infrastructure.

Oncology: Growing complexity of oncology products can create opportunities for specialized production and packaging.

API localization: Brazil’s reliance on imported APIs creates a strategic opportunity for domestic API and intermediate manufacturing.

International outsourcing: Brazilian manufacturers with strong regulatory capabilities can target pharmaceutical companies seeking Latin American production partners.

Brazil Pharmaceutical Contract Manufacturing Market Challenges

The sector also faces several challenges:

• Regulatory compliance
• High capital requirements
• Technology-transfer complexity
• API import dependence
• Quality-control requirements
• Manufacturing capacity utilization
• Specialized workforce requirements
• Biologics manufacturing complexity
• Pricing pressure from generic medicines
• Competition from other Latin American manufacturing hubs

Brazil Pharmaceutical Contract Manufacturing Market Outlook to 2035

Brazil’s pharmaceutical contract manufacturing industry is positioned around a combination of domestic pharmaceutical demand, manufacturing investment, outsourcing adoption and supply-chain localization.

The competitive environment is also becoming more capability-driven. Companies with established manufacturing infrastructure, regulatory expertise, specialized production technologies and the ability to support international pharmaceutical clients are likely to have stronger positioning.

For investors and pharmaceutical companies, the key question is therefore not simply how large the Brazilian CMO sector becomes.

It is:

Which manufacturing capabilities will capture the greatest share of outsourcing demand through 2035?

How Towards Healthcare Can Help Pharmaceutical Companies

Towards Healthcare Research & Consulting can support pharmaceutical and biotechnology companies evaluating Brazil’s contract manufacturing ecosystem through:

• Market sizing and forecasting
• CMO/CDMO competitive intelligence
• Company benchmarking
• Manufacturing capacity analysis
• Pharmaceutical outsourcing intelligence
• API and supply-chain analysis
• Buyer intelligence
• Partnership and supplier identification
• Investment opportunity assessment
• TAM, SAM and SOM analysis
• Regulatory and competitive intelligence
• Go-to-market strategy

This enables pharmaceutical companies, CDMOs, investors and suppliers to understand where demand is developing, which manufacturers are expanding, what capabilities buyers need and where new investment opportunities may emerge.

Frequently Asked Questions

What is the Brazil pharmaceutical contract manufacturing market?

It refers to pharmaceutical manufacturing services provided by third-party manufacturers to pharmaceutical and biotechnology companies in Brazil, including drug-product manufacturing, APIs, formulation, packaging and related services.

Who are the major pharmaceutical contract manufacturing companies in Brazil?

Eurofarma is a significant company to track because it operates a dedicated CMO business and provides manufacturing services to national and international pharmaceutical companies. EMS/Novamed and Cristália are also important manufacturing companies to evaluate based on their domestic production capabilities.

What is driving pharmaceutical contract manufacturing in Brazil?

Key factors include pharmaceutical outsourcing, manufacturing-capacity expansion, demand for cost-efficient medicines, supply-chain localization and growing demand for specialized pharmaceutical production.

What are the major opportunities for CMOs in Brazil?

Major opportunities include specialized pharmaceuticals, oncology, biologics, biosimilars, complex formulations, API localization and manufacturing services for international pharmaceutical companies.

What should companies consider before outsourcing pharmaceutical manufacturing in Brazil?

Companies should evaluate manufacturing capacity, regulatory compliance, quality systems, technology-transfer capabilities, dosage-form expertise, API sourcing, production scalability and the CMO’s experience serving comparable pharmaceutical products.